摩根大通发表研究报告，首次覆盖英硅智能及晶泰控股，均予“增持”评级，目标价分别为71港元及10港元。该行表示，在BD活动增加与临床催化剂的推动下，中国的人工智能新药研发(AIDD)行业正由商业探索阶段迈向早期商业化。该行对中国AIDD持乐观看法，预计行业将迎来估值重评机会。该行看好英硅智能通过AIDD建立的高风险、高回报管道，同时亦看好晶泰科技以AIDD服务和机器人湿实验室为核心的多元化业务。
摩根大通发表研究报告，首次覆盖英硅智能及晶泰控股，均予“增持”评级，目标价分别为71港元及10港元。该行表示，在BD活动增加与临床催化剂的推动下，中国的人工智能新药研发(AIDD)行业正由商业探索阶段迈向早期商业化。该行对中国AIDD持乐观看法，预计行业将迎来估值重评机会。该行看好英硅智能通过AIDD建立的高风险、高回报管道，同时亦看好晶泰科技以AIDD服务和机器人湿实验室为核心的多元化业务。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.